Leerink Partners, the health-care advisory firm, has continued a recent recruitment drive with hires from boutiques ...
Investor's Business Daily on MSN8h
How A Side Effect Has Wiped Out Nearly 73% Of Neurogene's Value In A WeekNeurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome ...
CVS Health has added four new board members, including the CEO of a hedge fund that has been critical of the struggling ...
Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share (EPS) estimates for Vincerx Pharma in a ...
Research analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of Ardent Health Partners in a ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Analyst Mani Foroohar of Leerink Partners maintained a Buy rating on RegenXBio (RGNX – Research Report), boosting the price target to $38.00. Don't Miss our Black Friday Offers: Discover the latest ...
Industry Veterans Grant Curry and Jason Truman Join Leerink Partners. BOSTON, Nov. 14, 2024 /PRNewswire/ -- Leerink Partners, a leading investment bank specializing in healthcare, announced today ...
Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.28% ...
Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...
Robert F. Kennedy Jr.'s nomination to lead HHS is causing cautious concern among investors. Here's which companies and stocks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback